@AngelZotano presented AURORA/PS17-04 analysis on ER+/HER2- MBC pts revealed a 20% prevalence of ESR1 mutations related to adjuvant AI treatment and ET resistance 👉🏼 crucial for tailored 1st-line trt in ER+/HER2- MBC #SABCS2023 @BIGagainstBC @GEICAM
#SABCS23-AURORA: ER activity & survival prognosis👉🏼crucial for tailored ET adjuvant trt. ESR1 mut status 👉🏼crucial for tailored 1st-line trt in ER+/HER2- MBC. ✋🏼 Important note: pts w/ bone-only disease in AURORA are limited=only 2.8%. @AngelZotano @EU_HADEA #EU4Health
; 
Entidades con las que GEICAM colabora
